Sign in
Create a Profile
Studies of in-vivo 5-fluorouracil pharmacokinetics, with and without bevacizumab in patients with liver metastases from adenocarcinoma of the colon
Diseases and Conditions Researched
Colon Cancer
What is the purpose of this trial?
This is a clinical research study that is designed to test if the administration of another medicine, called bevacizumab, an antibody that blocks blood vessels growth (angiogenesis) will increase the amount of your prescribed 5-FU that gets into the cancer cells in the liver. The objective is to perform 19F-MRS on patients with colorectal cancer liver metastases in order to determine the concentration of 5FU in liver metastases and AUC for the 48 hour infusion when given with and without bevacizumab. To correlate intratumoral pharmakinetic parameters with plasma 5FU levels and plasma 5FU AUC, and correlation of intratumoral 5FU with time to progression on current regimen Patients will be treated twice only on this study, once using a conventional 5FU based chemotherapy for colorectal cancer and a second time using bevacizumab followed by the same chemotherapy.Participation Guidelines
| Sponsor: | Yale Cancer Center |
|---|---|
| Study HIC#: | 1110009169 |
How will my information be used?
For more information about this trial, contact:
Yale Cancer Center
203-785-5702
Principal Investigator
Howard S Hochster
Jeremy Kortmansky
Jill Lacy
Stacey M Stein
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
